For the quarter ended September 2025, Privia Health (PRVA) reported revenue of $580.42 million, up 32.5% over the same period last year. EPS came in at $0.05, compared to $0.03 in the year-ago quarter.
The reported revenue represents a surprise of +16.64% over the Zacks Consensus Estimate of $497.62 million. With the consensus EPS estimate being $0.06, the EPS surprise was -16.67%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Privia Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Practice Collections: $940.4 million compared to the $844.52 million average estimate based on five analysts.
- Care Margin: $125.2 million versus the five-analyst average estimate of $113.04 million.
- Platform Contribution: $70.6 million versus $55.84 million estimated by five analysts on average.
- Implemented Providers (as of end of period): 5,250 versus the three-analyst average estimate of 5,216.
- Value-Based Care Attributed Lives (as of end of period): 1.41 million versus 1.38 million estimated by three analysts on average.
View all Key Company Metrics for Privia Health here>>>
Shares of Privia Health have returned +2% over the past month versus the Zacks S&P 500 composite's +1.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Privia Health Group, Inc. (PRVA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
